Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF INFORMATION ABOUT REPORTED SEGMENT PROFIT OR LOSS AND ASSETS (Details)

v3.21.2
SCHEDULE OF INFORMATION ABOUT REPORTED SEGMENT PROFIT OR LOSS AND ASSETS (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Segment Reporting Information [Line Items]              
Revenues $ 1,732       $ 6,763  
Operating loss         (3,190)    
Financing expenses, net         (10,485)    
Share in losses of affiliated companies accounted for under equity method, net (119)     (492)  
Net loss 3,390 $ (17,557) $ (2,585) $ (4,638) (14,167) $ (7,223)  
Total assets 17,258       17,258   $ 6,009
Total expenditures for assets of reportable segments         770    
Total depreciation for reportable segments         (356)    
Breast Cancer Test [Member]              
Segment Reporting Information [Line Items]              
Revenues            
Operating loss         (2,977)    
Total assets 11,029       11,029    
Total expenditures for assets of reportable segments            
Total depreciation for reportable segments         (15)    
Alzheimer [Member]              
Segment Reporting Information [Line Items]              
Revenues            
Operating loss            
Total assets          
Total expenditures for assets of reportable segments            
Total depreciation for reportable segments            
COVID-19 Testing [Member]              
Segment Reporting Information [Line Items]              
Revenues         6,763    
Operating loss         (213)    
Total assets $ 6,229       6,229    
Total expenditures for assets of reportable segments         770    
Total depreciation for reportable segments         $ (341)